Tags

Type your tag names separated by a space and hit enter

Question 12: What do you consider when discussing treatment adherence in patients with Cystic Fibrosis?

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

    Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

    Source

    Paediatric respiratory reviews 25: 2018 01 pg 33-36

    MeSH

    Adaptation, Psychological
    Aftercare
    Age Factors
    Anti-Bacterial Agents
    Attitude to Health
    Cost of Illness
    Cystic Fibrosis
    Diabetes Mellitus
    Diet Therapy
    Disease Progression
    Enzyme Replacement Therapy
    Exercise Therapy
    Expectorants
    Family
    Humans
    Medication Adherence
    Nutritional Support
    Pancreas
    Patient Compliance
    Perception
    Physical Therapy Modalities
    Severity of Illness Index
    Time Factors
    Treatment Adherence and Compliance

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    28625493

    Citation

    Ohn, Mon, and Dominic A. Fitzgerald. "Question 12: what Do You Consider when Discussing Treatment Adherence in Patients With Cystic Fibrosis?" Paediatric Respiratory Reviews, vol. 25, 2018, pp. 33-36.
    Ohn M, Fitzgerald DA. Question 12: What do you consider when discussing treatment adherence in patients with Cystic Fibrosis? Paediatr Respir Rev. 2018;25:33-36.
    Ohn, M., & Fitzgerald, D. A. (2018). Question 12: What do you consider when discussing treatment adherence in patients with Cystic Fibrosis? Paediatric Respiratory Reviews, 25, pp. 33-36. doi:10.1016/j.prrv.2017.04.002.
    Ohn M, Fitzgerald DA. Question 12: what Do You Consider when Discussing Treatment Adherence in Patients With Cystic Fibrosis. Paediatr Respir Rev. 2018;25:33-36. PubMed PMID: 28625493.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Question 12: What do you consider when discussing treatment adherence in patients with Cystic Fibrosis? AU - Ohn,Mon, AU - Fitzgerald,Dominic A, Y1 - 2017/04/27/ PY - 2017/04/19/received PY - 2017/04/19/accepted PY - 2017/6/20/pubmed PY - 2018/10/30/medline PY - 2017/6/20/entrez SP - 33 EP - 36 JF - Paediatric respiratory reviews JO - Paediatr Respir Rev VL - 25 SN - 1526-0550 UR - https://www.unboundmedicine.com/medline/citation/28625493/Question_12:_What_do_you_consider_when_discussing_treatment_adherence_in_patients_with_Cystic_Fibrosis L2 - https://linkinghub.elsevier.com/retrieve/pii/S1526-0542(17)30039-8 DB - PRIME DP - Unbound Medicine ER -